The N-methyl-D-aspartic acid (NMDA)-hypofunction theory of schizophrenia suggests that schizophrenia is associated with a loss of NMDA receptors, specifically on corticolimbic parvalbumin (PV)-expressing GABAergic interneurons, leading to disinhibition of pyramidal cells and cortical desynchronization. However, the presumed changes in glutamatergic inputs onto PV interneurons have not been tested directly. We treated mice with the NMDAR antagonist ketamine during the second postnatal week and investigated persistent cellular changes in the adult medial prefrontal cortex (mPFC) using whole-cell patch-clamp recordings and immunohistochemistry. Parvalbumin expression in the mPFC was reduced in ketamine-treated (KET) mice, and γ-aminobutyric ac...
It has been well established that schizophrenia patients display impaired NMDA receptor (NMDAR) func...
Acute administration of N-methyl-D-aspartate receptor (NMDAR) antagonists in healthy humans and anim...
Hypofunctioning of the N-methyl-D-aspartate receptor (NMDA-R) has been prominently implicated in the...
Acute treatment with subanesthetic ketamine, a non-competitive N-methyl-D-aspartic acid (NMDA) recep...
Acute treatment with subanaesthetic doses of NMDA receptor antagonists, such as ketamine, provides a...
A growing body of literature has demonstrated the potential for ketamine in the treatment of major d...
Administration in adulthood of subanaesthetic doses of ketamine, an NMDA receptor (NMDA-R) antagonis...
Systemic doses of the psychotomimetic ketamine alter the spectral characteristics of hippocampal and...
Hypofunction of the N-methyl-D-aspartate receptor (NMDAR) has been implicated as a possible mechanis...
Alterations in the function of the medial prefrontal cortex (mPFC) and its major thalamic source of ...
Ketamine is a non-competitive antagonist of the NMDA glutamate receptor with psychotomimetic and rei...
International audienceIn prodromal and early schizophrenia, disorders of attention and perception ar...
Hypofunctioning of the N-methyl-D-aspartate receptor (NMDA-R) has been prominently implicated in the...
It has been well established that schizophrenia patients display impaired NMDA receptor (NMDAR) func...
Acute administration of N-methyl-D-aspartate receptor (NMDAR) antagonists in healthy humans and anim...
Hypofunctioning of the N-methyl-D-aspartate receptor (NMDA-R) has been prominently implicated in the...
Acute treatment with subanesthetic ketamine, a non-competitive N-methyl-D-aspartic acid (NMDA) recep...
Acute treatment with subanaesthetic doses of NMDA receptor antagonists, such as ketamine, provides a...
A growing body of literature has demonstrated the potential for ketamine in the treatment of major d...
Administration in adulthood of subanaesthetic doses of ketamine, an NMDA receptor (NMDA-R) antagonis...
Systemic doses of the psychotomimetic ketamine alter the spectral characteristics of hippocampal and...
Hypofunction of the N-methyl-D-aspartate receptor (NMDAR) has been implicated as a possible mechanis...
Alterations in the function of the medial prefrontal cortex (mPFC) and its major thalamic source of ...
Ketamine is a non-competitive antagonist of the NMDA glutamate receptor with psychotomimetic and rei...
International audienceIn prodromal and early schizophrenia, disorders of attention and perception ar...
Hypofunctioning of the N-methyl-D-aspartate receptor (NMDA-R) has been prominently implicated in the...
It has been well established that schizophrenia patients display impaired NMDA receptor (NMDAR) func...
Acute administration of N-methyl-D-aspartate receptor (NMDAR) antagonists in healthy humans and anim...
Hypofunctioning of the N-methyl-D-aspartate receptor (NMDA-R) has been prominently implicated in the...